For more information, availability and pricing options for sponsorship/exhibition opportunities at the event, please contact Jon Liong at firstname.lastname@example.org.
Chubb is the world’s largest publicly traded P&C insurance company and the largest commercial insurer in the U.S. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients.
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
IQVIA Greater China R&D
After 21 years of expansion in Greater China (first office opened in 1997), we now have more 2,200 employees in Greater China. We have developed an integrated drug development offering to help companies of all sizes and types grow and succeed. Our infrastructure and capabilities in Greater China include: offices in Beijing, Shanghai, Dalian, Hong Kong and Taipei, allowing it to serve all major population centers and study sites; a world-class Central Lab in Beijing, with biomarker and pathology capabilities; and customized local solutions through our local subsidiary, Kun Tuo.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$15 billion assets, including several PE/VC funds, hedge funds and mutual funds. Since the inception of its private equity investment activities in 1993, OrbiMed has successfully invested in over 200 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed has continued strong performance in public equity as well. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in science, medicine, industry, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, manages OrbiMed Asia Partners (OAP), the first pan-Asia healthcare and life sciences-dedicated private equity fund. OAP has made PE investments in 29 companies, with close to USD$500 million under management. OrbiMed has also invested over USD$1 billion in the stocks of Asia public healthcare companies. For More information, please vist www.orbimed.com.
PROTECH PHARMASERVICES CORPORATION
PPC groupwas foundedin 1997, provides professional services for clinical studies to pharmaceutical and biotechnology companies.PPC group offers clinical and laboratory services in China, Taiwan, Korea and Japan. Since 1997, PPC has completed over 2000 early phase trials, including innovative phase Ipharmacokinetic, generic bioequivalence and biosimilar studies, to pharmaceuticals companies. In addition, PPC group has conducted over 400 innovative phase II-IV trials, covering all 24 therapeutic arenas. We have been audited more than 30 times by numerous regulatory authorities, including FDA, PMDA, CFDA，ANSM, NPRAand etc.
To fulfill harmonized bioequivalence standard for phase Iclinical site, PPC group has set up a phase Icenter in Taipei MacKay memorial Hospital in 2012; and co-found a phase Icenter with Xuzhou medical hospital in early 2017.Combining the strengths of Xuzhou Medical University, PPC has established strong early phase drug development especially in the bioavailability and bioequivalence research field over the past two decades. In 2018, PPC had set up 3 more dedicated Phase I Units in Xuzhou Central Hospital, Huangshi Central Hospital and Shanghai Pudong People’s Hospital.
Syneos Health is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®visit syneoshealth.com.
coming soon ...
ALMAC CLINICAL SERVICES
Almac Clinical Services, part of the Almac Group, has over 30 years’ experience deploying our clinical supply chain expertise and full suite of end-to-end clinical solutions to our global clients. By listening to our customers, we understand their challenges, creating patient-centric solutions that meet evolving study and industry needs.
The ECCRT is a specialised clinical research training organisation focusing on the transfer of implementable knowledge in the day-to-day activities of our participants whether being starters on the job or seasoned professionals.
Our mission is to facilitate Clinical Researchers to excel in their job for the benefit of patients. We aim to achieve this by providing clinical research professionals with competencies to develop new treatments for patients more efficient, without jeopardizing quality.
The ECCRT is in its actions supportive of the Benjamin Franklin's statement: “You tell me, and I forget. You teach me, and I remember. You involve me, and I learn.”
ESTART MEDICAL TECHNOLOGY
eStart Medical Technology Co., Ltd. (eStartMed www.estartmed.net) is a Chinese domestic contract research organization (CRO) mainly specialized in Phase I trail services. eStartMed offers seamless one stop services, including registration and strategical consulting, phase I-IV study project management, QC and QA audit, protocol design, data management, biostatistics, electronic data capture (EDC).
Recent years, the core team has successfully conducted more than 100 studies including Apatinib, Pyrrolidine, Martinib, Pramipexole, Celecoxib, Lenalidomide, etc.; and in 2013 completed the first China domestic TQT clinical trial according to international standards ( Morpholine nitrazole) and multiple IQT (or CQT) studies.
EstartMed has established Phase I Clinical Trials Center along with PKUCare LuZhong Hospital. The Ward currently has 100 beds, and has been established and configured in accordance with international standards, regulated and conformed to CFDA and FDA regulations, which provides international level of Phase I clinical trial service for you.
Jsure Health is the leading patient recruitment organization (PRO) in China, which provides reliable service raging from feasibility study, patient recruitment, patient self-report and survey, and patient retention service with multiple online and offline channels. Jsure helps over 70 studies every year to recruit thousands patients and assists sponsors to speed up their trial progress. Jsure currently has over 200,000 patient database and provide “Drug Finder” which is the online tool for clinical trial access for patients and referral doctors. Jsure is the co-founder of the Asian Patient Recruitment Organization (APRO) in 2014 which covers China, Japan, Korea and other countries to meet the increasing demands of Clinical Trials in Asia. Jsure is well recognized in the industry by its efficient service level and high quality management standard by 30+ leading global Pharma and leading bio-pharma in China. Jsure health has been listed on China new three board stock market since 2015.
PRA HEALTH SCIENCES
PRA has been delivering innovative drug development solutions in China for nearly a decade and continue that work through our locations in Beijing, Shanghái and Dalian.
We strive to move drug discovery forward side-by-side with our clients, helping them to develop live-saving and life-improving drugs. We provide comprehensive clinical development and data services across all phases with our unique blend of expertise and technology. From full-service clinical development to our pioneering Embedded Solutions™ model, PRA offers a broad spectrum of solutions that meet the demands of a diverse marketplace.
As a top five CRO, we have worked on 100+ marketed drugs across several therapeutic areas and conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of more than 75 such drugs.
PRA provides the local and global presence you need, with 15,500+ employees covering over 85 countries, combined with an in-depth knowledge of local regulations, standards of care, and the cultural customs our clients expect.
Our mission in China is to build the most comprehensive and flexible offering to support our clients with global trials, embedded teams, in-house biometrics, and local trials in China.
Shengsheng Logistics is focused on provide a safe, profession-al and efficient logistics solutions for life science, biotechnologyand biopharmaceutical companies. Shengsheng is headquar-tered in Shanghai with offices in Beijing, Guangzhou, Tianjin,Nanjing, Wuhan, Xi’an, Chengdu, Chongqing and Changchun. Our professional operators cover more than 80 cities and pro- vide China nationwide high quality and door to door cold chain
logistics service within 24 to 48 hours. Our warehouse in shanghai for bio-sample and clinical trial drugs can accommodate four million 2.0ml samples and 3000 cu- bic meter drugs, and providing the storage and distribution service for bio-sample and clinical trial drugs.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality.
Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 60 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 3200 full time staffs. Tigermed has set up international standard SOPs and serviced more than 600 local and global clients in the conduct of over 920 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of 130 innovative drugs.
For more information about Tigermed, please visit www.tigermed.net